CI The Cigna Group
XNYS 306.95 DelayedStock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Expected move IV rank history Fibonacci levels Insider trading
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
CI
$306.95
—
Key stats
$306.95
- 52-Week Range
- $239.51 – $316.26
- YTD
- +9.97%
- IV Rank (30D)
- 64.89
- Straddle Price
- $23.70
- P/C Vol Ratio
- 0.32
- Market Cap
- $83.5B
- Open
- $314.75
- Day Range
- $305.51 – $315.86
- Volume
- 1,780,485
- Prev Close
- $315.88
Fair Value
MODEL: LONG
A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.
- DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
- Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
- DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
- P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
- Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
- Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
- Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
- Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
| 10-yr Treasury (rf) | 5.12% |
| Beta vs SPY | 0.56 |
| Cost of Equity (CAPM) | 7.90% (VRP-adj) |
| WACC | 7.25% |
| Volatility Risk Premium | +15.5pp (IV − HV30) |
| Effective Tax Rate | 19.8% |
| Rev. Growth (YoY, DCF input) | +2.0% |
| DCF Horizon | 5 years explicit + fade |
| Forward Tilt (NTM/TTM) | ×1.02 (applied to P/E, EV/EBITDA, P/S) |
| Free Cash Flow (TTM) | $9.1B |
| Return on Equity (TTM) | 15.0% |
| Book / Price | 50.3% — banking bias active (P/B is primary) |
| Gross Margin (TTM) | 8.8% |
| FCF Margin (TTM) | 3.3% |
| Debt / Equity | 0.69 |
| Quality Score | 1/6 — cyclical/struggling (5y DCF) |
| SMA 50 | $281.18 (Market Anchor value) |
| SMA 20 / Bollinger Mid | $284.95 |
| Bollinger Width / SMA20 | 6.9% (drives anchor stability) |
| Net Debt | $22.3B |
| Market Cap | $84B |
Peers used for multiples: CNC, ELV, UNH
(filtered from 8 ETF-co-members; sector bias active)
60-Day Conviction
69%
20-Day Fair Value
≈ by Nov 23, 2026
$310.70
α +1.2%
rank 20%
conviction
70%
40-Day Fair Value
≈ by Dec 22, 2026
$315.77
α +2.9%
rank 18%
conviction
83%
60-Day Fair Value
≈ by Jan 20, 2027
$313.59
α +2.2%
rank 8%
conviction
69%
| Method | Implied Price | Weight | Detail |
|---|---|---|---|
| DCF | $636.61 | 21% | |
| DDM (Gordon) | $107.34 | 0% | |
| Peer P/E | n/a | 0% | |
| Peer EV/EBITDA | $455.98 | 3% | median 12.5× · 3 peers |
| Peer P/B | $335.32 | 9% | median 2.1× · 3 peers |
| Peer P/S | $497.10 | 3% | median 0.5× · 3 peers |
| Market Anchor (SMA50) | $281.18 | 42% | stability 100% (BB-width) |
| Options Expected (B-L 30d) | $314.79 | 21% | 38 strikes · skew -0.59 |
As of 2026-10-23 · updated
Related
About
- Industry (SIC)
- HOSPITAL & MEDICAL SERVICE PLANS (6324) · industry map
- Exchange
- XNYS
- Market Cap
- $83.5B
- Employees
- 67,700
- List Date
- 1982-04-01
- CIK
- 0001739940
- Next Earnings
- 2026-11-05 (Pre-Market)
- EPS Forecast
- $7.46 (7 est.)
- Headquarters
- Bloomfield, CT
- Homepage
- https://www.thecignagroup.com
Cigna primarily provides pharmacy benefit management and health insurance services. Its PBM and specialty pharmacy services, which were greatly expanded by its 2018 merger with Express Scripts, are mostly sold to health insurance plans and employers. Its largest PBM contract is with the Department of Defense, and it recently won a multiyear deal with top-tier insurer Centene. In health insurance and other benefits, Cigna primarily serves employers through self-funding arrangements, and the company operates mostly in the US with 16 million US and 2 million international medical members covered …
Summary
—
composite
—
No summary data available for this symbol yet.
Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.
Chart
Seasonality
| Month | '21 | '22 | '23 | '24 | '25 | '26 | Avg |
|---|---|---|---|---|---|---|---|
| Jan | 5.51% | -1.60% | -1.50% | -2.95% | 7.18% | -1.79% | 0.81% |
| Feb | -3.18% | 5.25% | -6.76% | 9.38% | 5.60% | 6.73% | 2.84% |
| Mar | 12.46% | 1.06% | -11.50% | 9.08% | 5.61% | -8.29% | 1.40% |
| Apr | 2.97% | 0.22% | -3.32% | -1.93% | 2.73% | 8.70% | 1.56% |
| May | 2.70% | 9.01% | -2.94% | -3.52% | -5.53% | -1.94% | -0.37% |
| Jun | -8.00% | -0.40% | 10.74% | -3.20% | 4.95% | 0.54% | 0.77% |
| Jul | -3.70% | 2.73% | 5.27% | 6.87% | -20.04% | 1.12% | -1.29% |
| Aug | -7.72% | 3.67% | -6.56% | 8.78% | 14.74% | -2.12% | 1.80% |
| Sep | -5.16% | -3.67% | 3.40% | -5.21% | -4.15% | -3.97% | -3.13% |
| Oct | 5.43% | 12.48% | 7.53% | -9.56% | -16.20% | 14.55%* | 2.37% |
| Nov | -11.21% | 1.16% | -15.04% | 6.73% | 7.22% | -- | -2.23% |
| Dec | 17.93% | 2.44% | 11.31% | -18.07% | 0.61% | -- | 2.84% |
| Total | 3.99% | 36.19% | -12.64% | -7.58% | -3.22% | 12.16% | 4.82% |
Technical Indicators
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
Trend Indicators
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
Volume & Volatility
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
SMA 20: $286.70
SMA 50: $281.76
SMA 200: $281.07
Current: $306.95
EMA 12: $297.91
EMA 26: $289.52
MACD: 8.3899 | Signal: 3.1482
BULLISH
ADX (14): 24.91
WEAK TREND
+DI: 31.86
−DI: 10.45
Momentum Oscillators
RSI (14): 64.77
NEUTRAL
Stoch %K: 90.89
Stoch %D: 93.99
Williams %R: -20.13
Volume & Volatility
BB Upper: $315.78
BB Lower: $257.61
NEUTRAL
OBV: -4,242,816
Vol SMA 20: 1,612,892
Vol ROC: 101.07%
ATR: $7.66
True Range: $10.37
HV 20: 26.3%
HV 30: 28.0%
HV 60: 26.4%
Data Summary
Data Points: 500
Last Updated:
Date Range: 2024-10-25T00:00:00 – 2026-10-23T00:00:00
AI Analysis
LLM Stock Analysis Report
Executive Summary
Overall assessment: NEUTRAL (confidence level: 6/10)
Key drivers:
- Technical signals indicate a range-bound market with no clear uptrend or downtrend
- News sentiment is mixed, with some positive news and negative news
Primary risks:
- The stock has low volatility relative to the market, which may indicate reduced risk but also limited potential for growth
- The options market suggests a high probability of a moderate price move by expiration
Investment thesis: The stock appears to be in a consolidation phase, with no clear direction or trend. While there are some positive news headlines, they do not seem to have had a significant impact on the stock's price. The low volatility and mixed news sentiment suggest that the stock may continue to range-trade for the near term.
Recent news sentiment impact: The recent news headlines have been mixed, with no clear pattern or direction. The negative headline about the sale proposal for The Dolphin Company has not seemed to have had a significant impact on the stock's price, while the positive earnings reports from Cigna have also not led to a notable move.
Technical Analysis
Trend Direction: Short-term: NEUTRAL (range-bound) Medium-term: NEUTRAL (range-bound) Long-term: NEUTRAL (consolidation)
Support/Resistance Levels:
- SMA 20: $282.29
- SMA 50: $285.71
- Upper Bollinger Band: $297.67
Momentum Signals:
- RSI: 48.23 (neutral)
- MACD: -2.53 / Signal: -0.14 / Histogram: -2.39 (bearish)
Volume Analysis:
- Volume SMA 20: 1781300.77
- On-Balance Volume (OBV): -17370796.13
News & Sentiment Analysis
Recent Headlines Summary: The recent news headlines have been mixed, with some positive and negative news.
Sentiment Assessment: Neutral sentiment dominates, but there is a slight bias towards the negative side.
Catalyst Identification: There are no immediate catalysts that could significantly impact the stock's price. The upcoming earnings reports from Cigna may have some influence on the stock's direction, but it is difficult to predict with certainty.
Market Narrative: The mixed news sentiment and low volatility suggest a consolidation phase, with the stock likely to continue ranging-trading for the near term.
Risk & Volatility Assessment
Risk Assessment: The stock has low risk relative to the market, with a beta of 0.21. The options market suggests a high probability of a moderate price move by expiration.
Volatility Regime: The current volatility level is relatively low compared to historical levels.
Options Market Signals: IV Rank: 90.3% (High - shows if volatility is historically high/low) Current IV: 58.3% Expected Move: $17.85 (31 DTE), 7-DTE: $10.70
Market Context & Positioning
Sector Performance: The stock has been trending lower compared to the sector and market, with a beta of 0.21.
Institutional Activity: There is no significant institutional activity that could influence the stock's direction.
Correlation Analysis: The stock moves relatively independently of the market, with an R-squared value of 0.08.
Relative Valuation: The stock appears to be fairly valued relative to its peers and the broader market.
Key Levels & Action Items
Critical Price Levels:
- SMA 20: $282.29
- SMA 50: $285.71
- Upper Bollinger Band: $297.67
Breakout/Breakdown Levels: The stock may breakout above the upper Bollinger Band if there is a significant positive news headline or earnings report.
Time-Sensitive Catalysts:
- Upcoming earnings reports from Cigna, which could influence the stock's direction.
- Any changes in the regulatory environment that could impact the company's operations.
Risk Management: Stop-loss levels should be set at around $265-270 to limit potential losses. Position sizing considerations should focus on limiting exposure and managing risk.
Generated
News
All CI news →
Cigna is ramping up investments in specialty pharmacy and a companywide focus into better ways to manage complex care of patients in its health plans.
Earnings History
14 of 23 under expected move
Avg Expected Move
4.51%
Avg Actual Move
4.81%
| Earnings Date | Timing | Expected Move | Actual Move | Ratio | Outcome |
|---|---|---|---|---|---|
| 2021-02-04 | Pre-Market | 3.08% | 6.40% | 2.08x | Exceeded |
| 2021-05-07 | Pre-Market | 2.04% | 1.65% | 0.81x | Within |
| 2021-08-05 | Pre-Market | 2.83% | 10.92% | 3.86x | Exceeded |
| 2021-11-04 | Pre-Market | 4.32% | 2.33% | 0.54x | Within |
| 2022-02-03 | Pre-Market | 3.78% | 5.42% | 1.43x | Exceeded |
| 2022-05-06 | Pre-Market | 4.01% | 5.88% | 1.47x | Exceeded |
| 2022-08-04 | Pre-Market | 4.45% | 3.08% | 0.69x | Within |
| 2022-11-03 | Pre-Market | 4.77% | 1.05% | 0.22x | Within |
| 2023-02-03 | Pre-Market | 4.32% | 2.96% | 0.69x | Within |
| 2023-05-05 | Pre-Market | 4.08% | 7.00% | 1.72x | Exceeded |
| 2023-08-03 | Pre-Market | 4.11% | 3.93% | 0.96x | Within |
| 2023-11-02 | Pre-Market | 3.64% | 3.06% | 0.84x | Within |
| 2024-02-02 | Pre-Market | 3.68% | 5.38% | 1.46x | Exceeded |
| 2024-05-02 | Pre-Market | 3.65% | 3.55% | 0.97x | Within |
| 2024-08-01 | Pre-Market | 5.03% | 4.61% | 0.92x | Within |
| 2024-10-31 | Pre-Market | 6.44% | 0.61% | 0.09x | Within |
| 2025-01-30 | Pre-Market | 5.46% | 6.70% | 1.23x | Exceeded |
| 2025-05-02 | Pre-Market | 5.12% | 0.13% | 0.03x | Within |
| 2025-07-31 | Pre-Market | 5.24% | 10.23% | 1.95x | Exceeded |
| 2025-10-30 | Pre-Market | 5.15% | 17.39% | 3.38x | Exceeded |
| 2026-02-05 | Pre-Market | 6.75% | 4.72% | 0.70x | Within |
| 2026-04-30 | Pre-Market | 6.07% | 0.60% | 0.10x | Within |
| 2026-07-30 | Pre-Market | 5.77% | 2.97% | 0.51x | Within |
Earnings calendar: this week’s reports with expected vs actual moves →
CI Options Activity & IV Rank
CI IV rank history, 52-week IV rank and IV percentile →
Volatility Metrics
Current IV: 34.4%
7-DTE IV: 28.0%
Expected Move: $23.70
7-DTE Move: $9.55
Days to Exp: 28 (2026-11-20)
Options Flow
Call Volume: 470
Put Volume: 150
P/C Volume: 0.319
BULLISH
Call OI: 2,006
Put OI: 1,827
P/C OI: 0.911
Total OI: 3,833
ATM Options Pricing
ATM Call: $11.60
ATM Put: $12.10
Call %: 3.8%
Put %: 3.9%
Chain Summary
Chain Volume: 5,387
Chain OI: 75,838
Last Updated: 10/23/2026
Spread Scanner GPU
Each spread is ranked by a composite score built in three stages. Full documentation →
Stage 1 — Base Score (GPU scanner)
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Stage 2 — Skew Adjustment (±25% cap)
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Enter a ticker to scan for optimal spread opportunities.
Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.
Dealer Positioning
HIGH γ vs HISTORY
Estimated net dealer gamma is at the 95th percentile of this name's own daily history, near the high end of its range. This describes current positioning; it is not a forecast or a trading signal.
Gamma percentile
95%
vs own history
GEX tilt
+0.61
OI-weighted, today
Vanna tilt
+0.21
δ-sensitivity to IV
Charm tilt
-0.41
δ-decay vs time
Charm tilt -0.41: the estimated dealer exposure leans negative, so the modeled hedge would shift noticeably as time passes and options approach expiry.
? What is this?
· 113 ATM contracts, 22k total OI
Net dealer gamma is an estimate of the aggregate gamma held by options market makers across this name's option chain, weighted by open interest. Dealer positions aren't public, so it uses a standard simplifying assumption: dealers are treated as long the calls and short the puts that are open. Actual dealer books can differ.
Gamma percentile ranks today's estimate against this name's own daily history, from 0% (the lowest reading on record) to 100% (the highest). Raw gamma scales with how much open interest a chain carries, so it isn't comparable across names; the percentile is. The badge marks the bottom 20% as low and the top 20% as high.
Tilts run from −1 to +1 and show how lopsided the estimated dealer exposure is. GEX tilt compares call gamma with put gamma. Vanna tilt describes how the hedge would shift if implied volatility changed, and charm tilt how it would shift with the passage of time.
This card describes estimated positioning and where it sits historically. It is not a forecast of price direction or volatility and not a trading signal. Market-wide view: Dealer positioning screener.
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Wing vs ATM
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together
Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d
92%
+13.2
pts
EXTREME
as of Oct 23 · ATM 43.2% / Wing 56.4%
30 DTE / 10d
5%
+1.1
pts
EXTREME
as of Oct 23 · ATM 35.0% / Wing 36.1%
Extreme reading.
Historically these have been contrarian — on the small set of observed earnings-day cases, large negative wing-vs-ATM gaps (calls pricing much richer than puts at the same delta) preceded sharp drops in the underlying within 1-12 days. Not financial advice and the dataset is small.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Volatility Surface
Enter a ticker to render the implied volatility surface.
Volatility Smile
Enter a ticker to render the implied volatility smile.
IV Rank (7 DTE)20.0LowOct 23
IV Rank (30 DTE)64.9MediumOct 23
Straddle Price (30 DTE)$23.70Oct 23
Beta Analysis
Risk Metrics
Beta: 0.1460
Alpha: 4.22%
Correlation: 0.0568
R-Squared: 0.3%
Stock Volatility: 32.8%
Market Volatility: 12.7%
Analysis Details
Benchmark: SPY
Data Points: 251
Period: 252 trading days
Data Points: 251
Period: 252 trading days
Interpretation:
Low volatility - stock moves less than market
Low volatility - stock moves less than market
Beta & Alpha Over Time
Notable investors who own CI
6 of 37 tracked investors
| Investor | Value | Share of their portfolio | Rank | Q/Q shares | Source |
|---|---|---|---|---|---|
| Millennium Management Hedge fund Izzy Englander | $125.6M | #272 of 3716 | +262.8% | 13F | |
| Glenview Capital Hedge fund Larry Robbins | $113.6M | #15 of 42 | -17.4% | 13F | |
| Renaissance Technologies Hedge fund Jim Simons | $95.2M | #167 of 3138 | +57.8% | 13F | |
| Citadel Hedge fund Ken Griffin | $88.6M | #454 of 6285 | -3.5% | 13F | |
| Bridgewater Associates Hedge fund Ray Dalio | $24.2M | #171 of 997 | -61.5% | 13F | |
| Rockefeller Capital Management Family office Rockefeller family | $14.4M | #595 of 4729 | +6.3% | 13F |
Hedge funds, activists, holding companies and family offices we track, from their latest 13F (quarter-end value) and Form 4 filings in the last 3 years. Family offices · all institutions
CI Institutional Ownership (13F)
Latest filings — 2026-09-30
? 13F Guide
Diluted shares outstanding: 267,066,000 (as of 2026-03-31)
Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
41 filers$1.33B notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Susquehanna International Group, LLP Custodian | $295.64M | 22.28% | 2026-06-30 |
| 2 | BloombergSen Inc. | $250.40M | 18.87% | 2026-06-30 |
| 3 | Walleye Trading LLC | $136.10M | 10.26% | 2026-06-30 |
| 4 | Jane Street Group, LLC Custodian | $102.36M | 7.71% | 2026-06-30 |
| 5 | IMC-Chicago, LLC Custodian | $97.04M | 7.31% | 2026-06-30 |
| 6 | Citadel Advisors LLC Custodian | $80.42M | 6.06% | 2026-06-30 |
| 7 | Barclays PLC Custodian | $60.10M | 4.53% | 2026-06-30 |
| 8 | GROUP ONE TRADING LLC Custodian | $54.86M | 4.13% | 2026-06-30 |
| 9 | Wolverine Trading, LLC Custodian | $49.65M | 3.74% | 2025-09-30 |
| 10 | Caption Management, LLC | $44.11M | 3.32% | 2026-06-30 |
| 11 | Royal Bank of Canada Custodian | $41.35M | 3.12% | 2026-06-30 |
| 12 | Simplex Trading, LLC Custodian | $27.62M | 2.08% | 2026-06-30 |
| 13 | Goldman Sachs Group Inc Custodian | $13.78M | 1.04% | 2026-06-30 |
| 14 | Millennium Management LLC Custodian | $9.29M | 0.70% | 2026-06-30 |
| 15 | Twin Tree Management, LP | $8.02M | 0.60% | 2026-06-30 |
| 16 | SIG BROKERAGE, LP | $6.15M | 0.46% | 2026-06-30 |
| 17 | Walleye Capital LLC | $4.30M | 0.32% | 2026-06-30 |
| 18 | Allianz Asset Management GmbH | $4.22M | 0.32% | 2026-06-30 |
| 19 | D. E. Shaw & Co., Inc. Custodian | $4.14M | 0.31% | 2026-06-30 |
| 20 | Point72 Asset Management, L.P. | $4.05M | 0.31% | 2026-06-30 |
| 21 | CAPITAL FUND MANAGEMENT S.A. | $3.94M | 0.30% | 2026-06-30 |
| 22 | Cubist Systematic Strategies, LLC | $3.92M | 0.30% | 2025-09-30 |
| 23 | Squarepoint Ops LLC | $3.89M | 0.29% | 2026-06-30 |
| 24 | PEAK6 LLC | $3.28M | 0.25% | 2026-06-30 |
| 25 | TUDOR INVESTMENT CORP ET AL | $2.98M | 0.22% | 2026-06-30 |
43 filers$1.00B notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | National Bank of Canada Custodian | $272.10M | 27.14% | 2026-06-30 |
| 2 | Susquehanna International Group, LLP Custodian | $140.13M | 13.98% | 2026-06-30 |
| 3 | Jane Street Group, LLC Custodian | $131.06M | 13.07% | 2026-06-30 |
| 4 | Citadel Advisors LLC Custodian | $58.91M | 5.88% | 2026-06-30 |
| 5 | Wolverine Trading, LLC Custodian | $51.60M | 5.15% | 2025-09-30 |
| 6 | Barclays PLC Custodian | $51.00M | 5.09% | 2026-06-30 |
| 7 | BNP Paribas Financial Markets Custodian | $49.48M | 4.94% | 2026-06-30 |
| 8 | IMC-Chicago, LLC Custodian | $44.00M | 4.39% | 2026-06-30 |
| 9 | GROUP ONE TRADING LLC Custodian | $41.08M | 4.10% | 2026-06-30 |
| 10 | Walleye Trading LLC | $28.06M | 2.80% | 2026-06-30 |
| 11 | Marex Group Ltd | $27.57M | 2.75% | 2026-06-30 |
| 12 | Millennium Management LLC Custodian | $20.79M | 2.07% | 2026-06-30 |
| 13 | D. E. Shaw & Co., Inc. Custodian | $11.03M | 1.10% | 2026-06-30 |
| 14 | Simplex Trading, LLC Custodian | $10.61M | 1.06% | 2026-06-30 |
| 15 | Squarepoint Ops LLC | $8.35M | 0.83% | 2026-06-30 |
| 16 | Cubist Systematic Strategies, LLC | $7.00M | 0.70% | 2025-09-30 |
| 17 | Allianz Asset Management GmbH | $6.29M | 0.63% | 2026-06-30 |
| 18 | Walleye Capital LLC | $5.98M | 0.60% | 2026-06-30 |
| 19 | Eisler Capital Management Ltd. | $5.39M | 0.54% | 2025-09-30 |
| 20 | Point72 Asset Management, L.P. | $4.60M | 0.46% | 2026-06-30 |
| 21 | CREDIT AGRICOLE S A | $4.14M | 0.41% | 2026-06-30 |
| 22 | PEAK6 LLC | $3.28M | 0.33% | 2026-06-30 |
| 23 | Twin Tree Management, LP | $2.92M | 0.29% | 2026-06-30 |
| 24 | Alphadyne Asset Management LP | $2.29M | 0.23% | 2026-06-30 |
| 25 | CAPSTONE INVESTMENT ADVISORS, LLC | $2.10M | 0.21% | 2026-06-30 |
CI Insider Trading (Form 4)
Latest: 2026-09-08Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-09-08 | Everett Neville | See Remarks | Sell (S) | −617 | $284.05 | -$175.3K | EDGAR |
| 2026-09-03 | Brian C Evanko | See Remarks | Award (A) | +3,113 | — | EDGAR | |
| 2026-09-02 | George Kurian | Director | Grant (A) | +108 RSU | — | EDGAR | |
| 2026-08-20 | Nicole S Jones | See Remarks | Sell (S) | −2,677 | $279.61 | -$748.5K | EDGAR |
| 2026-08-20 | Bryan Holgerson | See Remarks | Award (A) | — | — | EDGAR | |
| 2026-08-06 | Nicole S Jones | See Remarks | Mixed | −4,090 | $239.10 | -$2.42M | EDGAR |
| 2026-08-06 | Nicole S Jones | See Remarks | Mixed | −4,090 | $239.10 | -$2.42M | EDGAR |
| 2026-06-16 | Jamie G Kates | Chief Accounting Officer | Mixed | — | $225.75 | -$131.0K | EDGAR |
| 2026-06-03 | Durga Prasad Koka | EVP, Global CIO | Tax (F) | −729 | $275.53 | -$200.9K | EDGAR |
| 2026-06-02 | George Kurian | Director | Grant (A) | +108 RSU | — | EDGAR | |
| 2026-05-14 | David Cordani | Chairman & CEO | Mixed | +10,665 | $230.01 | -$22.91M | EDGAR |
| 2026-04-24 | Eric C Wiseman | Director | Award (A) | +782 | — | EDGAR | |
| 2026-04-24 | Philip Ozuah | Director | Award (A) | +782 | — | EDGAR | |
| 2026-04-24 | Michael J Hennigan | Director | Award (A) | +782 | — | EDGAR | |
| 2026-04-24 | Kimberly A. Ross | Director | Award (A) | +782 | — | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.
CI Insider Holdings
22 insiders · @ $306.95
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | David Cordani | Chairman & CEO | 307,285 | $94.32M | -$427.28M | 81 | 2026-05-14 |
| 2 | Eric P Palmer | See Remarks | 70,504 | $21.64M | -$8.61M | 30 | 2025-03-04 |
| 3 | Brian C Evanko | See Remarks | 66,644 | $20.46M | -$3.63M | 24 | 2026-09-03 |
| 4 | Eric J Foss | Director | 36,696 | $11.26M | $3.02M | 49 | 2026-04-24 |
| 5 | Donna F Zarcone | Director | 27,517 | $8.45M | -$1.75M | 74 | 2026-04-24 |
| 6 | Nicole S Jones | See Remarks | 27,331 | $8.39M | -$71.20M | 63 | 2026-08-20 |
| 7 | Eric C Wiseman | Director | 23,940 | $7.35M | $249.1K | 78 | 2026-04-24 |
| 8 | David J Brailer | EVP & Chief Health Officer | 17,525 | $5.38M | $0 | 8 | 2025-09-03 |
| 9 | Noelle K Eder | See Remarks | 13,590 | $4.17M | -$6.91M | 17 | 2025-03-11 |
| 10 | Ann M Dennison | EVP, CFO | 7,745 | $2.38M | $0 | 1 | 2026-03-03 |
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.
CI Board & Officers
As of SEC filings through Sep 8, 2026Directors 11
- Kathleen M Mazzarella · since Dec 20, 2018
- Donna F Zarcone · listed since Dec 2019
- Eric C Wiseman · listed since Dec 2019
- Eric J Foss · listed since Dec 2019
- Mark B. McClellan · listed since Dec 2019
- David Cordani · listed since Feb 2020
- Kimberly A. Ross · since Jun 1, 2020
- George Kurian · since Mar 1, 2021
- Neesha Hathi · since Sep 1, 2021
- Philip Ozuah · since Jun 1, 2023
- Michael J Hennigan · since Jun 2, 2025
Officers 14
- David Cordani · Chairman & CEO · listed since Mar 2022
- Brian C Evanko · EVP, Chief Financial Officer and President & CEO, Cigna Healthcare · listed since Mar 2024
- Bryan Holgerson · Title - President, Cigna Healthcare U.S. and EVP, Customer Health Outcomes · since Jul 1, 2026
- Ann M Dennison · EVP, CFO · since Mar 31, 2025
- David J Brailer · EVP & Chief Health Officer · since Sep 1, 2022
- Jamie G Kates · Chief Accounting Officer · since Jul 1, 2024
- Nicole S Jones · EVP, Chief Administrative Officer and Chief Human Resources Officer · listed since Aug 2026
- Paul A Sanford · EVP Operations · since Sep 27, 2021
- Everett Neville · EVP, Solutions & Corp Devt. · listed since Feb 2023
- Durga Prasad Koka · EVP, Global CIO · since Sep 8, 2025
- Andrea L Nelson · EVP, General Counsl & Corp Sec · since Mar 24, 2026
- Jason D Sadler · Pres., International Health · listed since Feb 2023
- Adam Kautzner · since Jul 1, 2026
- Matthew Perlberg · since Jul 1, 2026
Changes in the last 10 years (97)
| Aug 6, 2026 | Nicole S Jones listed as EVP, Chief Administrative Officer and Chief Human Resources Officer (previously EVP, Chief Administrative Officer and General Counsel) in SEC filings |
| Jul 1, 2026 | Matthew Perlberg became an officer |
| Jul 1, 2026 | Bryan Holgerson became Title - President, Cigna Healthcare U.S. and EVP, Customer Health Outcomes |
| Jul 1, 2026 | Adam Kautzner became an officer |
| Mar 24, 2026 | Andrea L Nelson became EVP, General Counsl & Corp Sec |
| Oct 15, 2025 | The company announced the departure of Elder Granger from the board in an SEC filing |
| Sep 8, 2025 | Durga Prasad Koka became EVP, Global CIO |
| Jun 2, 2025 | Michael J Hennigan became a director |
| Apr 22, 2025 | The company announced the departure of Noelle K Eder as EVP, Global Chief Information Officer in an SEC filing |
| Mar 31, 2025 | Ann M Dennison became EVP, CFO |
| Jul 1, 2024 | Jamie G Kates became Chief Accounting Officer |
| Mar 5, 2024 | Noelle K Eder listed as EVP, Global Chief Information Officer (previously EVP, Global CIO) in SEC filings |
| Mar 5, 2024 | Nicole S Jones listed as EVP, Chief Administrative Officer and General Counsel (previously EVP, General Counsel) in SEC filings |
| Mar 5, 2024 | Brian C Evanko listed as EVP, Chief Financial Officer and President & CEO, Cigna Healthcare (previously EVP, Chief Financial Officer) in SEC filings |
| Mar 1, 2024 | Michael W Triplett listed as Special Advisor (previously President, U.S. Commercial) in SEC filings |
| Feb 13, 2024 | Eric P Palmer listed as EVP, Enterprise Strategy and President & CEO, Evernorth Health Services (previously President & CEO, Evernorth) in SEC filings |
| Jun 1, 2023 | Philip Ozuah became a director |
| Feb 24, 2023 | Noelle K Eder listed as EVP, Global CIO (previously EVP, CIO) in SEC filings |
| Feb 24, 2023 | Jason D Sadler listed as Pres., International Health (previously Pres., International Markets) in SEC filings |
| Feb 24, 2023 | Everett Neville listed as EVP, Solutions & Corp Devt. (previously EVP, Strat, Corp Dev/Solutions) in SEC filings |
| Sep 1, 2022 | David J Brailer became EVP & Chief Health Officer |
| Mar 1, 2022 | Everett Neville listed as EVP, Strat, Corp Dev/Solutions (previously EVP, Strategy and Business Dev) in SEC filings |
| Mar 1, 2022 | David Cordani listed as Chairman & CEO (previously President & CEO) in SEC filings |
| Feb 25, 2022 | Michael W Triplett listed as President, U.S. Commercial (previously President, US Markets) in SEC filings |
| Feb 25, 2022 | John M Murabito listed as EVP & Chief Admin Officer (previously EVP, HR & Services) in SEC filings |
| Feb 25, 2022 | Eric P Palmer listed as President & CEO, Evernorth (previously President & COO, Evernorth) in SEC filings |
| Jan 31, 2022 | Charles Berg became Pres, Govt Programs & Sr Advsr |
| Sep 27, 2021 | Paul A Sanford became EVP Operations |
| Sep 1, 2021 | Neesha Hathi became a director |
| Aug 2, 2021 | Cynthia Ryan became EVP, CHRO |
| Mar 1, 2021 | George Kurian became a director |
| Feb 26, 2021 | Eric P Palmer listed as President & COO, Evernorth (previously EVP, Chief Financial Officer) in SEC filings |
| Feb 26, 2021 | Brian C Evanko listed as EVP, Chief Financial Officer (previously President Government Business) in SEC filings |
| Jan 25, 2021 | Matthew G Manders listed as Pres, Government and Solutions (previously President, Strategy & Solution) in SEC filings |
| Jan 1, 2021 | Everett Neville became EVP, Strategy and Business Dev |
| Nov 6, 2020 | Timothy C Wentworth listed as CEO Evernorth (previously President, Health Services) in SEC filings |
| Sep 14, 2020 | Noelle K Eder became EVP, CIO |
| Jun 1, 2020 | Kimberly A. Ross became a director |
| Mar 23, 2020 | Kristen Lauria became EVP Chief Marketing Officer |
| Mar 2, 2020 | Mark L Boxer first listed as EVP, Chief Information Officer in an SEC filing |
| Feb 28, 2020 | Timothy C Wentworth listed as President, Health Services (previously Pres, Exp Scrpts & Cigna Svcs) in SEC filings |
| Feb 28, 2020 | Eric P Palmer first listed as EVP, Chief Financial Officer in an SEC filing |
| Feb 28, 2020 | David Cordani first listed as a director in an SEC filing |
| Feb 28, 2020 | David Cordani first listed as President & CEO in an SEC filing |
| Feb 28, 2020 | Brian C Evanko first listed as President Government Business in an SEC filing |
| Feb 26, 2020 | John M Murabito first listed as EVP, HR & Services in an SEC filing |
| Dec 5, 2019 | Michael W Triplett first listed as President, US Markets in an SEC filing |
| Dec 2, 2019 | Roman Martinez IV first listed as a director in an SEC filing |
| Dec 2, 2019 | Mark B. McClellan first listed as a director in an SEC filing |
| Dec 2, 2019 | Eric J Foss first listed as a director in an SEC filing |
| Dec 2, 2019 | Eric C Wiseman first listed as a director in an SEC filing |
| Dec 2, 2019 | Donna F Zarcone first listed as a director in an SEC filing |
| Nov 26, 2019 | John Partridge first listed as a director in an SEC filing |
| Nov 21, 2019 | Jason D Sadler first listed as Pres., International Markets in an SEC filing |
| Nov 21, 2019 | Hoeltzel Mary T Agoglia first listed as SVP Tax & Chief Acct. Officer in an SEC filing |
| Nov 20, 2019 | Nicole S Jones first listed as EVP, General Counsel in an SEC filing |
| Nov 14, 2019 | Matthew G Manders first listed as President, Strategy & Solution in an SEC filing |
| Mar 4, 2019 | Isaiah Harris Jr no longer listed as a director in SEC filings |
| Dec 26, 2018 | William D Zollars reported in an SEC filing no longer being a director |
| Dec 26, 2018 | Roman Martinez IV reported in an SEC filing no longer being a director |
| Dec 26, 2018 | Nicole S Jones reported in an SEC filing no longer being EVP, General Counsel |
| Dec 26, 2018 | Michael W Triplett reported in an SEC filing no longer being President, US Markets |
| Dec 26, 2018 | Matthew G Manders reported in an SEC filing no longer being President, Strategy & Solution |
| Dec 26, 2018 | Mark L Boxer reported in an SEC filing no longer being EVP, Chief Information Officer |
| Dec 26, 2018 | Mark B. McClellan reported in an SEC filing no longer being a director |
| Dec 26, 2018 | Lisa R Bacus reported in an SEC filing no longer being EVP, Chf Marketing & Cust Off |
| Dec 26, 2018 | John Partridge reported in an SEC filing no longer being a director |
| Dec 26, 2018 | John M Murabito reported in an SEC filing no longer being EVP, HR & Services |
| Dec 26, 2018 | Jason D Sadler reported in an SEC filing no longer being Pres., International Markets |
| Dec 26, 2018 | James E Rogers reported in an SEC filing no longer being a director |
| Dec 26, 2018 | Isaiah Harris Jr first listed as a director in an SEC filing |
| Dec 26, 2018 | Hoeltzel Mary T Agoglia reported in an SEC filing no longer being VP & Chief Accounting Officer |
| Dec 26, 2018 | Eric P Palmer reported in an SEC filing no longer being EVP, Chief Financial Officer |
| Dec 26, 2018 | Eric J Foss reported in an SEC filing no longer being a director |
| Dec 26, 2018 | Eric C Wiseman reported in an SEC filing no longer being a director |
| Dec 26, 2018 | Donna F Zarcone reported in an SEC filing no longer being a director |
| Dec 26, 2018 | David Cordani reported in an SEC filing no longer being a director |
| Dec 26, 2018 | David Cordani reported in an SEC filing no longer being President & CEO |
| Dec 26, 2018 | Brian C Evanko reported in an SEC filing no longer being President Government Business |
| Dec 26, 2018 | Alan Muney reported in an SEC filing no longer being EVP Total Hlth & Network & CMO |
| Dec 20, 2018 | William L Roper became a director |
| Dec 20, 2018 | William J DeLaney III became a director |
| Dec 20, 2018 | Timothy C Wentworth became Pres, Exp Scrpts & Cigna Svcs |
| Dec 20, 2018 | Steven B Miller became EVP, Chief Clinical Officer |
| Dec 20, 2018 | Kathleen M Mazzarella became a director |
| Dec 20, 2018 | Elder Granger became a director |
| Dec 1, 2018 | Mark B. McClellan became a director (predecessor company) |
| Nov 20, 2018 | Matthew G Manders listed as President, Strategy & Solution (previously Pres. Gov't & Ind Prog & Group) in SEC filings (predecessor company) |
| Nov 6, 2017 | Brian C Evanko became President Government Business (predecessor company) |
| Jun 16, 2017 | Eric P Palmer became EVP, Chief Financial Officer (predecessor company) |
| Feb 28, 2017 | Matthew G Manders listed as Pres. Gov't & Ind Prog & Group (previously Pres. US Comm Mkts & Gbl HC Op) in SEC filings (predecessor company) |
| Feb 28, 2017 | Lisa R Bacus listed as EVP, Chf Marketing & Cust Off (previously EVP, Chief Marketing Officer) in SEC filings (predecessor company) |
| Feb 23, 2017 | Michael W Triplett became President, US Markets (predecessor company) |
| Feb 23, 2017 | Christopher J Hocevar became Pres. Strat Segmts & Solutions (predecessor company) |
| Feb 23, 2017 | Alan Muney became EVP Total Hlth & Network & CMO (predecessor company) |
| Nov 14, 2016 | Herbert A Fritch reported in an SEC filing no longer being President, HealthSpring |
| Nov 11, 2016 | Matthew Shawn Morris became Interim Pres., HealthSpring (predecessor company) |
Not reported recently (20)
- Eric P Palmer · Last reported as EVP, Enterprise Strategy and President & CEO, Evernorth Health Services in an SEC filing dated Mar 4, 2025
- William J DeLaney III · Last reported as a director in an SEC filing dated Aug 21, 2024
- Michael W Triplett · Last reported as Special Advisor in an SEC filing dated Aug 14, 2024
- Hoeltzel Mary T Agoglia · Last reported as SVP Tax & Chief Acct. Officer in an SEC filing dated May 16, 2024
- Cynthia Ryan · Last reported as EVP, CHRO in an SEC filing dated Aug 31, 2023
- Charles Berg · Last reported as Pres, Govt Programs & Sr Advsr in an SEC filing dated Feb 8, 2023
- John Partridge · Last reported as a director in an SEC filing dated Apr 28, 2022
- John M Murabito · Last reported as EVP & Chief Admin Officer in an SEC filing dated Mar 3, 2022
- Matthew G Manders · Last reported as Pres, Government and Solutions in an SEC filing dated Nov 23, 2021
- Timothy C Wentworth · Last reported as CEO Evernorth in an SEC filing dated May 13, 2021
- Kristen Lauria · Last reported as EVP Chief Marketing Officer in an SEC filing dated May 3, 2021
- William L Roper · Last reported as a director in an SEC filing dated Mar 2, 2021
- Steven B Miller · Last reported as EVP, Chief Clinical Officer in an SEC filing dated Mar 2, 2021
- Roman Martinez IV · Last reported as a director in an SEC filing dated Dec 2, 2020
- Mark L Boxer · Last reported as EVP, Chief Information Officer in an SEC filing dated Mar 2, 2020
- Christopher J Hocevar · Last reported as Pres. Strat Segmts & Solutions in an SEC filing dated Mar 6, 2018
- Jane E Md Henney · Last reported as a director in an SEC filing dated Mar 2, 2018
- Thomas A McCarthy · Last reported as EVP, Chief Financial Officer in an SEC filing dated Mar 2, 2017
- Michelle Gass · Last reported as a director in an SEC filing dated Dec 2, 2016
- Matthew Shawn Morris · Last reported as Interim Pres., HealthSpring in an SEC filing dated Nov 21, 2016
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.
CI Proposed Insider Sales (Form 144)
Latest: 2026-09-03
? Form 144 Guide
Last 30d:
0 filings
· Last 90d:
3 filings
· $6.3M notice value
· 2 unique filers
· 100% under 10b5-1 plans
What is Form 144? A notice of intent to sell restricted or control stock under Rule 144. Affiliates (officers, directors, 10%+ owners) and holders of restricted shares must file Form 144 when planning to sell more than 5,000 shares or $50,000 in any 3-month rolling window.
How it relates to Form 4: Form 144 is filed before the trade (up to 90 days in advance); Form 4 is filed within 2 business days after the trade executes. Not every Form 144 results in a sale — the filer may cancel or delay. Look for the corresponding Form 4 on the Insider Activity card to confirm a sale actually happened.
10b5-1 plans: Trades made under a pre-scheduled Rule 10b5-1 plan are not discretionary — they execute automatically on dates set months earlier, regardless of news. High 10b5-1 percentages mean less per-filing signal value, though cumulative selling volume still matters.
"Notice value": Aggregate market value the filer wrote into the Form 144 — i.e. the size of the planned sale, not necessarily the executed dollars. An amended notice (Form 144/A) replaces the original it amends, and cancelled notices are dropped, so neither is double-counted above. A filed value that is clearly inconsistent with the share count at the stock's price (a filer typo) shows as a dash and is left out of the totals.
Source & freshness: Sourced from public Form 144 filings. Refreshed daily; new filings typically appear here the morning after they are filed.
Top 90-day filers:
Jones Nicole S (2, $6.1M) · Neville Everett (1, $175K)
| Filed | Filer | Role | Shares | Notice Value | Planned Sale | Broker | Plan | Link |
|---|---|---|---|---|---|---|---|---|
| 2026-09-03 | Neville Everett | Officer | 617 | $175.3K | 2026-09-03 | Fidelity Brokerage Services LLC | 10b5-1 | EDGAR |
| 2026-08-18 | Jones Nicole S | Officer | 2,677 | $748.4K | 2026-08-18 | Fidelity Brokerage Services LLC | 10b5-1 | EDGAR |
| 2026-08-04 | Jones Nicole S | Officer | 19,436 | $5.37M | 2026-08-04 | Fidelity Brokerage Services LLC | 10b5-1 | EDGAR |
| 2026-06-12 | Kates Jamie G | Officer | 899 | $268.5K | 2026-06-12 | Fidelity Brokerage Services LLC | — | EDGAR |
| 2026-05-12 | Cordani David | Officer, Director | 201,878 | $59.11M | 2026-05-12 | Fidelity Brokerage Services LLC | 10b5-1 | EDGAR |
| 2026-03-02 | Jones Nicole S | Officer | 2,307 | $666.5K | 2026-03-02 | Fidelity Brokerage Services LLC | 10b5-1 | EDGAR |
| 2026-03-02 | Neville Everett | Officer | 1,719 | $496.6K | 2026-03-02 | Fidelity Brokerage Services LLC | 10b5-1 | EDGAR |
| 2026-02-06 | Granger Elder | Former Director | 6,109 | $1.79M | 2026-02-06 | Fidelity Brokerage Services LLC | — | EDGAR |
| 2025-10-03 | Evanko Brian C | Officer | 5,368 | $1.61M | 2025-10-03 | Fidelity Brokerage Services LLC | 10b5-1 | EDGAR |
| 2025-08-15 | Jones Nicole S | Officer | 28,526 | $8.56M | 2025-08-15 | Fidelity Brokerage Services LLC | 10b5-1 | EDGAR |
Notice value is the aggregate market value the filer states they intend to sell — not a confirmed transaction. Compare to Insider Activity (Form 4) to see which planned sales actually executed. Market-wide feed: Planned sales (Form 144).
Recent SEC Filings
Latest: 2026-05-13
Current reports — material events the company must disclose within 4 business days (earnings releases, M&A, executive changes, etc.).
| Filing Date | Accession | Link |
|---|---|---|
| 2026-05-13 | 0001140361-26-020906 | EDGAR |
| 2026-04-30 | 0001140361-26-017971 | EDGAR |
| 2026-04-27 | 0001140361-26-017123 | EDGAR |
| 2026-03-03 | 0001140361-26-007450 | EDGAR |
| 2026-02-27 | 0001140361-26-007049 | EDGAR |
| 2026-02-05 | 0001140361-26-003768 | EDGAR |
| 2025-11-18 | 0001140361-25-042597 | EDGAR |
| 2025-10-30 | 0001140361-25-039777 | EDGAR |
| 2025-10-20 | 0001140361-25-038670 | EDGAR |
| 2025-09-04 | 0001140361-25-033986 | EDGAR |
Annual report — audited financial statements, MD&A, risk factors. Filed 60–90 days after fiscal year-end.
| Filing Date | Accession | Link |
|---|---|---|
| 2026-02-26 | 0001739940-26-000006 | EDGAR |
| 2025-02-27 | 0001739940-25-000009 | EDGAR |
| 2024-02-29 | 0001739940-24-000005 | EDGAR |
| 2023-02-23 | 0001739940-23-000008 | EDGAR |
| 2022-02-24 | 0001739940-22-000007 | EDGAR |
| 2021-02-25 | 0001739940-21-000007 | EDGAR |
| 2020-02-27 | 0001739940-20-000006 | EDGAR |
| 2019-02-28 | 0001047469-19-000792 | EDGAR |
Quarterly report — unaudited financials and MD&A. Filed 40–45 days after each of the first three fiscal quarters.
| Filing Date | Accession | Link |
|---|---|---|
| 2026-04-30 | 0001739940-26-000043 | EDGAR |
| 2025-10-30 | 0001739940-25-000037 | EDGAR |
| 2025-07-31 | 0001739940-25-000028 | EDGAR |
| 2025-05-02 | 0001739940-25-000021 | EDGAR |
| 2024-10-31 | 0001739940-24-000033 | EDGAR |
| 2024-08-01 | 0001739940-24-000028 | EDGAR |
| 2024-05-02 | 0001739940-24-000015 | EDGAR |
| 2023-11-02 | 0001739940-23-000025 | EDGAR |
| 2023-08-03 | 0001739940-23-000020 | EDGAR |
| 2023-05-05 | 0001739940-23-000016 | EDGAR |
ETF Holders
361 ETFs hold CI
25 shown · $10.38B total exposure · 0.17% AUM-weighted avg weight
| # | ETF | Provider | Weight | $ Exposure | ETF AUM | As Of |
|---|---|---|---|---|---|---|
| 1 | VTI Vanguard Morningstar Total Stock Market ETF | Vanguard | 0.10% | $2.3B | — | 2026-09-30 |
| 2 | VOO Vanguard S&P 500 ETF | Vanguard | 0.11% | $1.9B | — | 2026-09-30 |
| 3 | IVV iShares Core S&P 500 ETF | iShares (BlackRock) | 0.13% | $1.1B | $873.6B | 2026-10-22 |
| 4 | SPY State Street® SPDR® S&P 500® ETF Trust | SPDR (State Street) | 0.13% | $1.0B | $810.5B | 2026-10-22 |
| 5 | VTV Vanguard Morningstar Value ETF | Vanguard | 0.27% | $684.3M | — | 2026-09-30 |
| 6 | XLV State Street® Health Care Select Sector SPDR® ETF | SPDR (State Street) | 1.27% | $604.8M | $47.7B | 2026-10-22 |
| 7 | VYM Vanguard High Dividend Yield ETF | Vanguard | 0.30% | $288.7M | — | 2026-09-30 |
| 8 | SPYM State Street® SPDR® Portfolio S&P 500® ETF | SPDR (State Street) | 0.13% | $230.3M | $182.5B | 2026-10-22 |
| 9 | RSP Invesco S&P 500 Equal Weight ETF | Invesco | 0.22% | $223.0M | — | 2026-10-22 |
| 10 | VHT Vanguard Health Care ETF | Vanguard | 1.01% | $219.7M | — | 2026-09-30 |
| 11 | VFLO VictoryShares Free Cash Flow ETF | Nport | 2.66% | $206.4M | — | 2026-06-30 |
| 12 | IWD iShares Russell 1000 Value ETF | iShares (BlackRock) | 0.22% | $185.0M | $84.5B | 2026-10-22 |
| 13 | DGRO iShares Core Dividend Growth ETF | iShares (BlackRock) | 0.39% | $174.1M | $44.5B | 2026-10-22 |
| 14 | RWL Invesco S&P 500 Revenue ETF | Invesco | 1.57% | $162.7M | — | 2026-10-22 |
| 15 | DFAC Dimensional US Core Equity 2 ETF | Dimensional | 0.16% | $139.1M | — | 2026-10-22 |
| 16 | IVE iShares S&P 500 Value ETF | iShares (BlackRock) | 0.27% | $138.7M | $50.4B | 2026-10-22 |
| 17 | FNDX Schwab Fundamental U.S. Large Company ETF | Nport | 0.47% | $119.0M | — | 2026-05-31 |
| 18 | ITOT iShares Core S&P Total U.S. Stock Market ETF | iShares (BlackRock) | 0.11% | $108.1M | $95.8B | 2026-10-22 |
| 19 | SPYV State Street® SPDR® Portfolio S&P 500® Value ETF | SPDR (State Street) | 0.27% | $106.1M | $38.8B | 2026-10-22 |
| 20 | VLUE iShares MSCI USA Value Factor ETF | iShares (BlackRock) | 1.05% | $96.2M | $9.2B | 2026-10-22 |
| 21 | CGGO Capital Group Global Growth Equity ETF | Capitalgroup | 0.76% | $88.0M | $11.6B | 2026-10-22 |
| 22 | VV Vanguard Morningstar Large-Cap ETF | Vanguard | 0.11% | $84.6M | — | 2026-09-30 |
| 23 | SCHX Schwab U.S. Large-Cap ETF | Nport | 0.11% | $77.4M | — | 2026-05-31 |
| 24 | IUSV iShares Core S&P U.S. Value ETF | iShares (BlackRock) | 0.26% | $73.7M | $28.3B | 2026-10-22 |
| 25 | QLTY GMO U.S. Quality ETF | Nport | 1.60% | $72.2M | — | 2026-05-31 |
Fundamentals
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
Metrics
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.
Trailing P/E
13.00
TTM Diluted EPS
$23.61
TTM Revenue
$276.88B
TTM Net Income
$6.29B
TTM Op. Cash Flow
$8.81B
Quarterly figures (12 quarters)
| Quarter | Period End | Revenue | Net Income | Diluted EPS | Op. Cash Flow |
|---|---|---|---|---|---|
| Q1 '26 | 2026-03-31 | $68.29B | $1.65B | $6.26 | $1.13B |
| Q4 '25 | 2025-12-31 | $72.13B | $1.23B | $4.66 | $6.15B |
| Q3 '25 | 2025-09-30 | $69.52B | $1.87B | $6.98 | $3.42B |
| Q2 '25 | 2025-06-30 | $66.94B | $1.53B | $5.71 | $-1.89B |
| Q1 '25 | 2025-03-31 | $65.26B | $1.32B | $4.85 | $1.92B |
| Q4 '24 | 2024-12-31 | $65.37B | $1.42B | $5.07 | $5.21B |
| Q3 '24 | 2024-09-30 | $63.61B | $739.00M | $2.63 | $46.00M |
| Q2 '24 | 2024-06-30 | $60.20B | $1.55B | $5.45 | $265.00M |
| Q1 '24 | 2024-03-31 | $56.97B | $-277.00M | $-0.97 | $4.84B |
| Q4 '23 | 2023-12-31 | $50.82B | $1.03B | $3.50 | $1.47B |
| Q3 '23 | 2023-09-30 | $48.73B | $1.41B | $4.74 | $2.83B |
| Q2 '23 | 2023-06-30 | $48.31B | $1.46B | $4.92 | $2.49B |
Q1 2026 • period ending 2026-03-31 • filed 2026-04-30
Valuation
Ratios derived from TTM financials and the current market price, sampled daily. History chart shows how expensive the stock is today relative to its own recent past.
Price Multiples
- P/E — price / TTM earnings. Rough market rule: 10–15 value, 15–25 market, >30 growth/premium. Negative when earnings are negative.
- P/B — price / book value. Useful for financials and asset-heavy names; meaningless for asset-light software.
- P/S — price / TTM revenue. Useful when earnings are negative or noisy (early-stage growth).
- EV/EBITDA — capital-structure-neutral. <10 cheap, 10–15 reasonable, >20 rich. Good for comparing across leverage profiles.
- EV/Sales — like P/S but accounts for debt + cash. Compare within sector.
Profitability & Yields
- ROE — return on equity. >15% strong, >25% exceptional. Caution: high leverage inflates ROE.
- ROA — return on assets. Leverage-neutral; >5% solid, >10% exceptional.
- Div Yield — annual dividend / price. Compare to 10Y Treasury; sustained yield >6% often signals distress.
- FCF Yield — free cash flow / market cap. >5% is attractive; negative means burning cash.
Balance Sheet
- Debt/Equity — leverage. <1 conservative, >2 aggressive. Sector-dependent (utilities naturally high, tech low).
- Current Ratio — short-term liquidity. >1.5 comfortable, <1 raises short-term solvency flags.
Reading the history chart
- Compare current level to the 3-year band: near the high end = relatively expensive; near the low = relatively cheap.
- Multiples expanding while earnings are flat = sentiment-driven rally.
- Multiples compressing while earnings grow = value coming from fundamentals.
P/E
13.00
P/B
1.93
P/S
0.30
EV/EBITDA
9.21
EV/Sales
0.38
ROE
14.8%
ROA
4.1%
Div Yield
1.95%
FCF Yield
10.75%
Debt/Equity
0.69
Current Ratio
—
Market Cap
$81.98B
as of 2026-10-23
Short Interest & Float
Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.
Metric definitions
- Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
- SI % of Float — short interest / free float. The key crowding metric.
- Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
- Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
- Free Float — shares available for public trading (total shares minus insider / restricted).
- Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
How to read the signals
- SI % of Float < 5% — typical, no particular signal.
- 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
- 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
- >30% — extreme; borrow is likely expensive and squeeze risk is material.
- Days to Cover > 5 combined with high SI% amplifies squeeze potential.
History chart
- Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
- A sudden drop in SI after a rally may indicate a squeeze in progress.
Short interest is reported mid-month and end-of-month; short volume is daily.
Short Interest
6.95M
SI % of Float
2.65%
Days to Cover
3.90
Short Vol Ratio
65.8%
Free Float
262.55M
Float %
99.4%
Short interest 2026-09-30 • Short volume 2026-10-23 • Float 2026-08-24